Our data suggest that GPC3-targeted MRI could serve as a companion diagnostic tool, facilitating selection of GPC3-positive HCC subgroups eligible for GPC3-targeted immunotherapies or cell therapies (e.g., Phase I trial, NCT02748837), as well as longitudinal monitoring of treatment response and tumor recurrence. The gene discussed is GPC3; the disease is hepatocellular carcinoma.